NASDAQ:ENTA Enanta Pharmaceuticals Q2 2025 Earnings Report $12.00 +0.05 (+0.42%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$11.99 -0.01 (-0.08%) As of 09/24/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Enanta Pharmaceuticals EPS ResultsActual EPS-$1.06Consensus EPS -$1.04Beat/MissMissed by -$0.02One Year Ago EPSN/AEnanta Pharmaceuticals Revenue ResultsActual Revenue$14.93 millionExpected Revenue$15.96 millionBeat/MissMissed by -$1.04 millionYoY Revenue GrowthN/AEnanta Pharmaceuticals Announcement DetailsQuarterQ2 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time12:30PM ETUpcoming EarningsEnanta Pharmaceuticals' Q4 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Enanta Pharmaceuticals Earnings HeadlinesEnanta Pharmaceuticals (NASDAQ:ENTA) Earns Buy Rating from HC WainwrightSeptember 25 at 1:54 AM | americanbankingnews.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026August 10, 2026 | businesswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 25 at 1:00 AM | Weiss Ratings (Ad)Enanta Faces Patent Setback in Paxlovid LitigationJune 23, 2026 | tipranks.comEnanta Pharmaceuticals Announces Public Stock OfferingApril 11, 2026 | msn.comEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory ...April 7, 2026 | finanznachrichten.deSee More Enanta Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email. Email Address About Enanta PharmaceuticalsEnanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases. Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection. The company also discovered paritaprevir, which was incorporated into earlier AbbVie hepatitis C regimens. Enanta receives royalties associated with certain products developed through its collaborations. Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta conducts research and clinical development activities through collaborations and its internal drug-discovery programs. Its pipeline has included orally administered antiviral candidates targeting RSV and other viruses. The company is led by Jay R. Luly, Ph.D., who has served as president and chief executive officer.View Enanta Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedDave’s Success Has Investors Split Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
